PIIND2024-01-012024-03-31 PIIND2024-01-012024-03-31 PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses01Member PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses02Member PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses03Member PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses04Member PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses05Member PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses06Member PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses07Member PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses08Member PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses09Member PIIND2024-01-012024-03-31in-bse-fin:OneOperatingExpenses10Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses01Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses02Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses03Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses04Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses05Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses06Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses07Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses08Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses09Member PIIND2024-01-012024-03-31in-bse-fin:FourOperatingExpenses10Member PIIND2024-03-31 PIIND2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue01Member PIIND2024-01-012024-03-31in-bse-fin:OneReportableSegmentRevenue02Member PIIND2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue01Member PIIND2024-01-012024-03-31in-bse-fin:FourReportableSegmentRevenue02Member PIIND2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults01Member PIIND2024-01-012024-03-31in-bse-fin:OneReportableSegmentResults02Member PIIND2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults01Member PIIND2024-01-012024-03-31in-bse-fin:FourReportableSegmentResults02Member PIIND2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets01Member PIIND2024-01-012024-03-31in-bse-fin:OneReportableSegmentAssets02Member PIIND2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member PIIND2024-03-31in-bse-fin:OneReportableSegmentLiabilities01Member PIIND2024-01-012024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member PIIND2024-03-31in-bse-fin:OneReportableSegmentLiabilities02Member PIIND2024-01-012024-03-31in-bse-fin:OneItemsThatWillNotBeReclassifiedToProfitAndLoss01Member PIIND2024-01-012024-03-31in-bse-fin:FourItemsThatWillNotBeReclassifiedToProfitAndLoss01Member PIIND2024-01-012024-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss01Member PIIND2024-01-012024-03-31in-bse-fin:OneItemsThatWillBeReclassifiedToProfitAndLoss02Member PIIND2024-01-012024-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss01Member PIIND2024-01-012024-03-31in-bse-fin:FourItemsThatWillBeReclassifiedToProfitAndLoss02Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 523642 PIIND NOTLISTED PI Industries Limited Equity 2023-04-01 2024-03-31 2024-05-21 2024-05-02 INR Millions Yearly 14:00:00 21:25:00 2024-05-21 2024-05-21 true Cash Flow Indirect Declaration of unmodified opinion Multi segment 2024-01-01 2024-03-31 Audited Consolidated 17410000000.00 579000000.00 17989000000.00 8497000000.00 381000000.00 -844000000.00 1784000000.00 109000000.00 799000000.00 3174000000.00 13900000000.00 4089000000.00 0.00 4089000000.00 766000000.00 -348000000.00 418000000.00 0.00 3671000000.00 0.00 0.00 0.00 24000000.00 3695000000.00 19000000.00 3714000000.00 3695000000.00 0.00 3714000000.00 0.00 152000000.00 1 24.36 24.35 0.00 0.00 24.36 24.35 1 The above Consolidated financial results were reviewed and recommended by the Audit Committee of the Board and approved by the Board of Directors at their meeting held on May 21, 2024. 2 Consolidated Financial results for all the periods presented have been prepared in accordance with the recognition and measurement principles of Ind AS notified under the Companies (Indian Accounting Standards) Rules, 2015 as amended from time to time. 3 The Consolidated financial results include the results of the following entities namely, Parent Company a) Pl Industries Limited; Subsidiaries (including step down subsidiaries): b) PILL Finance and Investments Limited c) Pl Life Science Research Limited d) Pl Japan Co. Limited e) Jivagro Limited f) PI Bioferma Private Limited g) Pl Fermachem Private Limited h) Pl Health Sciences Limited i) Pl Health Sciences USA, LLC j) Pl Health Sciences Netherlands BV k) Archimica S.p.A Italy; Controlled trust: I) PII ESOP Trust; m) Pl Kumiai Private Limited (Joint Venture) n) Solinnos Agro Sciences Private Limited (Associate). 4 The Figures for the March quarter are the balancing figures between audited figures in respect of full financial year and the published unaudited year to date figures up to the third quarter of respective financial year. 5 Consolidated statement of Cash Flow. 6 The Company raised Rs. 20,000 Mn during the quarter ended September 30, 2020 through Qualified Institutional Placement (QIP) of equity shares. Out of the funds received of Rs. 19,750 Mn (net of expense of Rs. 250 Mn), the Company invested Rs. 9,840 Mn in one of its subsidiary, Pl Health Sciences Limited. Balance funds of Rs. 9,910 Mn received pursuant to QIP remain invested in fixed deposits, liquid and other debt mutual funds. 7 During the June 2023 quarter, Pl Health Sciences Limited has entered into a share purchase agreement dated April 27, 2023 for the acquisition of 100% shareholding of Therachem Research Medilab (India) Private Limited and Solis Pharmachem Private Limited . Further, Pl Health Sciences USA, LLC has entered into an asset purchase agreement dated April 27, 2023 for the acquisition of business of Therachem Research Medilab LLC, USA. These agreements were subject to satisfactory completion of conditions precedents as set out in the respective agreement, which were completed on June 02, 2023 end of business hours. Pl Health Sciences Netherlands BV has entered into a share purchase agreement dated April 26, 2023 for the acquisition of 100% shareholding of Archimica S.p.A, Italy and acquired 100% shares on April 27, 2023. These transactions have been accounted for in accordance with the acquisition method specified in Ind AS 103 Business Combination and the purchase consideration in excess of the fair value of the net assets acquired has been recognised as goodwill. 8 During the year, Material lost in transit amounting to Rs. 401 Mn was recovered, out of which, Rs. 351 Mn has been re-processed and sold to the customer. Balance material is under evaluation. 9 Segment information as per Ind AS 108 Operating Segments . 10 The Board of Directors at their meeting held on May 21, 2024 have recommended final dividend of Rs. 9 per equity share, subject to the approval of the shareholders in the ensuing Annual General Meeting. With this, total dividend for the year (including interim dividend of Rs. 6 per equity share paid during the year) is Rs. 15 per share. 11 The previous period's figures have been regrouped/ rearranged/ reclassified wherever necessary. Multi segment 2023-04-01 2024-03-31 Audited Consolidated 76658000000.00 2077000000.00 78735000000.00 35787000000.00 2629000000.00 -40000000.00 7013000000.00 300000000.00 3082000000.00 11122000000.00 59893000000.00 18842000000.00 0.00 18842000000.00 3657000000.00 -1525000000.00 2132000000.00 0.00 16710000000.00 0.00 0.00 0.00 105000000.00 16815000000.00 245000000.00 17060000000.00 16815000000.00 0.00 17060000000.00 0.00 152000000.00 1 87158000000.00 110.85 110.83 0.00 0.00 110.85 110.83 Advertisement & Sales Promotion 116000000.00 Environment & Pollution Control Expenses 341000000.00 Freight & Cartage 119000000.00 Laboratory & Testing Charges 169000000.00 Legal & professional fees 265000000.00 Net Impairment losses on Financial Assets 19000000.00 Others 765000000.00 Power, Fuel & Water 624000000.00 Repairs & Maintenance 485000000.00 Travelling and Conveyance 271000000.00 Advertisement & Sales Promotion 789000000.00 Environment & Pollution Control Expenses 1264000000.00 Freight & Cartage 603000000.00 Laboratory & Testing Charges 531000000.00 Legal & professional fees 1012000000.00 Net Impairment losses on Financial Assets 168000000.00 Others 2399000000.00 Power, Fuel & Water 2320000000.00 Repairs & Maintenance 1203000000.00 Travelling and Conveyance 833000000.00 29543000000.00 1731000000.00 0.00 3611000000.00 2129000000.00 1050000000.00 0.00 335000000.00 568000000.00 0.00 0.00 581000000.00 1149000000.00 469000000.00 838000000.00 40855000000.00 13012000000.00 12460000000.00 10911000000.00 8865000000.00 18174000000.00 37000000.00 187000000.00 50634000000.00 0.00 3139000000.00 66785000000.00 0.00 0.00 107640000000.00 152000000.00 87158000000.00 87310000000.00 87310000000.00 617000000.00 0.00 2041000000.00 2658000000.00 364000000.00 202000000.00 0.00 0.00 3224000000.00 662000000.00 11484000000.00 3544000000.00 15690000000.00 988000000.00 366000000.00 62000000.00 0.00 17106000000.00 20330000000.00 107640000000.00 Agro Chemicals 16695000000.00 Pharma 715000000.00 Agro Chemicals 73509000000.00 Pharma 3149000000.00 17410000000.00 76658000000.00 0.00 0.00 17410000000.00 76658000000.00 Agro Chemicals 4503000000.00 Pharma -390000000.00 Agro Chemicals 20051000000.00 Pharma -1104000000.00 4113000000.00 18947000000.00 0.00 0.00 0.00 0.00 4113000000.00 18947000000.00 Agro Chemicals 94353000000.00 Pharma 13287000000.00 107640000000.00 0.00 107640000000.00 Agro Chemicals 16016000000.00 Pharma 4314000000.00 20330000000.00 300000000.00 2045000000.00 -276000000.00 0.00 -1125000000.00 1000000.00 307000000.00 -339000000.00 0.00 2398000000.00 0.00 -230000000.00 0.00 3082000000.00 168000000.00 -176000000.00 112000000.00 995000000.00 -41000000.00 -49000000.00 0.00 1249000000.00 0.00 -659000000.00 0.00 0.00 0.00 3000000.00 0.00 5267000000.00 24109000000.00 0.00 0.00 0.00 3750000000.00 0.00 20359000000.00 0.00 6337000000.00 0.00 0.00 0.00 0.00 0.00 0.00 14000000.00 6204000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1532000000.00 0.00 -7010000000.00 0.00 -18005000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 248000000.00 0.00 0.00 267000000.00 1744000000.00 453000000.00 0.00 0.00 -2216000000.00 138000000.00 0.00 138000000.00 0.00 138000000.00 Remeasurements gain/(loss) on cash flow hedges -117000000.00 Remeasurements gain/(loss) on cash flow hedges -96000000.00 -117000000.00 -96000000.00 -40000000.00 -33000000.00 Effective portion of gain/(loss) on cashflow hedges 251000000.00 Exchange difference on translation of foreign operations -68000000.00 Effective portion of gain/(loss) on cashflow hedges 524000000.00 Exchange difference on translation of foreign operations -33000000.00 183000000.00 491000000.00 87000000.00 183000000.00